

FEB. 24. 2005 4:25PM

GENAISSANCE PHARM.

NO. 215

P. 1/10

Appl. No.10/019,242

Request for Correction of Filing Receipt dated February 24, 2005

Application No. : 10/019,242
Applicant : Richard Judson, et al.
Filed : December 21, 2001
Title : Methods for Obtaining and Using Haplotype Data
Art Unit : 2857
Examiner :
Attorney Docket No. : 2458-4042US2

Office of Initial Patent Examination's Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Facsimile: 703.746.9195

REQUEST FOR CORRECTION OF FILING RECEIPT

Applicants filed a Response to File Missing Parts of Nonprovisional Application on July 27, 2004. At that time, applicants provided a copy of the Request for Correction of Inventorship, filed November 4, 2003, which instructed that R. Rex Denton and Gualberto Ruano be removed as inventors; and, a copy of the Combined Declaration and Power of Attorney, executed on October 22, 2002 and October 23, 2003, which claims priority to U.S. Provisional Application 60/141,521.

Attached please find the same documents, as well as the Filing Receipt, mailed July 2, 2004, with the changes noted. Please correct the errors on the Filing Receipt.

Respectfully submitted,

February 24, 2005
Reg. No. 37,878
Tel. No. 203-786-3421
m.henderson@genaissance.com

Melodie W. Henderson
Melodie W. Henderson
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

10

Application Number

10/019,242

Filing Date

December 21, 2001

First Named Inventor

Richard Judson

Art Unit

2857

Examiner Name

Attorney Docket Number

2458-4042US2

ENCLOSURES (Check all that apply)

- | | | |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance Communication to TC |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Petition | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Power of Attorney, Revocation | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | Request for Correction of Filing Receipt; Copy of Filing Receipt with changes noted; and Documentation supporting changes requested |
| <input type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Reply to Missing Parts/Incomplete Application | <input type="checkbox"/> Landscape Table on CD | |
| <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | Remarks | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Genaissance Pharmaceuticals, Inc.

Signature

Melodie W. Henderson

Printed name

Melodie W. Henderson

Date

02/24/2005

Reg. No.

37,848

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Kathleen Porzelt

Typed or printed name

Kathleen Porzelt

Date

2/24/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete. Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1459
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/019,242	12/21/2001	2857	824	2458-4042US2	62	17	4

CONFIRMATION NO. 4987

25106

GENAISSANCE PHARMACEUTICALS
5 SCIENCE PARK
NEW HAVEN, CT 06511

FILING RECEIPT



OC000000013142582

Date Mailed: 07/02/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

~~Richard Rex Denton, Residence Not Provided; Remove~~
Richard S. Judson, Residence Not Provided;
~~X Guaberto Ruano, Residence Not Provided; Remove~~
Joel Claiborne Stephens, Residence Not Provided;
Andreas K. Windemuth, Residence Not Provided;
Chuanbo Xu, Residence Not Provided;

→ Domestic Priority data as claimed by applicant

→ U.S. Provisional Application 60/141,521
Filed 6/25/99

Foreign Applications

UNITED STATES OF AMERICA PCT/US00/17540 06/26/2000, which
claims priority to

If Required, Foreign Filing License Granted: 06/25/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

RECEIVED

JUL 06 2004

Genaisance Pharmaceuticals
Intellectual Property Dept.

Methods for obtaining and using haplotype data

Preliminary Class

702

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.


NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/019,242
Confirmation No.: 4987
Applicant: RR Denton et al.
Filing Date: December 21, 2001
Title: Methods for Obtaining and Using Haplotype Data
Attorney Docket No.: 2458-4042US2

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450


Certificate of Facsimile Transmission
I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Commissioner for Patents, TC 1600, at (703)-746-4060 on July 27, 2004.

Eileen McCauley

TRANSMITTAL

In response to the Notice to File Missing Parts of a Nonprovisional Application filed under 37 CFR 1.53(b) dated July 2, 2004, enclosed herewith please find:

1. Response to Notice to File Missing Parts of Nonprovisional Application filed under 37 CFR 1.53(b) (2 pages)
2. Copy of Notice to File Missing Parts of Nonprovisional Application filed under 37 CFR 1.53(b)
3. Request for Correction of Inventorship (1 page)
4. Combined Declaration and Power of Attorney (10 pages), executed 10/22/02 and 10/23/02
5. Copy of Revocation of Power of Attorney & Appointment of New Power of Attorney and Statement under 37 CFR 3.73(b) filed 10/29/03 (2 pages)
6. Fee Transmittal Form (in duplicate)
7. Copy of Verified Certification of Express Mailing Date for submission of application December 21, 2001 (1 page)
8. Copy of page 2 of Form PTO-1449 submitted June 11, 2003 (1 page)

Date: July 27, 2004
Registration No. 7,934
203-773-1450
s.shaner@genaisance.com

By: 
Sandra L. Shaner
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511
USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Denton, et al.

Group No.:

Attorney Docket No.: 2458-4042US2

Application No.: 10/019,242

Date Filed: December 21, 2001

Examiner:

For: Methods for Obtaining and Using Haplotype Data

U.S. Patent & Trademark Office
Commissioner for Patents
Mail Stop Applications
P.O.Box 1450
Alexandria, VA 22313-1450

Certificate of Facsimile Transmission

I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Commissioner for Patents, TC 1600, at (703) 872-9306, on February 24, 2005.


Eileen McCaffern

REQUEST FOR CORRECTION OF INVENTORSHIP
PURSUANT TO 37 C.F.R. 1.48(b)

Applicants filed the above-noted application on December 21, 2001. However, in reviewing the file, applicants noted two inventors were erroneously listed because they were only inventors of some of the claims in International Application No. PCT/US00/17540 filed June 26, 2000 and these claims were canceled in the Preliminary Amendment filed with the present application. Applicants herewith request that the following two inventors be removed from the application noted above:


- (1) R. Rex Denton
- (2) Gualberto Ruaño

Fee Transmittal Form PTO/SB/17 is attached authorizing payment of the processing fee set forth in § 1.17(i).

Date: November 4, 2003

Reg. No. 47,934

Tel. No. 203-786-3468


Signature of Practitioner
Sandra L. Shaner
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511
USA

Appl. No. 10/019,243

Request for Correction of Filing Receipt dated February ²⁴~~X~~, 2005

Application No. : 10/019,243
Applicant : Richard Judson, et al.
Filed : December 21, 2001
Title : Methods for Obtaining and Using Haplotype Data
Art Unit : 2857
Examiner :
Attorney Docket No. : 2458-4042US3

Office of Initial Patent Examination's Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Facsimile: 703.746.9195

REQUEST FOR CORRECTION OF FILING RECEIPT

Attached please find a copy of the Filing Receipt, dated September 20, 2004, with corrections noted. Also attached is a copy of the Combined Declaration and Power of Attorney, which states that the above-referenced U.S. Nonprovisional application claims priority to U.S. Provisional Application 60/141,521, filed June 25, 1999 and PCT/US00/17540, filed June 26, 2000.

Respectfully submitted,

February 24, 2005
Reg. No. 37,848
Tel. No. 203-786-3421
m.henderson@genaissance.com

Melodie W. Henderson
Melodie W. Henderson
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

PTO/SB/21 (09-04)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

8

Application Number

10/019,243

Filing Date

December 21, 2001

First Named Inventor

Richard Judson

Art Unit

2857

Examiner Name

Attorney Docket Number

2458-4042US3

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Request for Correction of Filing Receipt; Copy of Filing Receipt with changes noted; and Documentation supporting changes requested
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Genaissance Pharmaceuticals, Inc.		
Signature	<i>Melodie W. Henderson</i>		
Printed name	Melodie W. Henderson		
Date	02/24/2005	Reg. No.	37,848

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	<i>Kathleen Porzelt</i>		
Typed or printed name	Kathleen Porzelt	Date	2/24/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22312-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FILE FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/019,243	12/21/2001	2857	1402	2458-4042US3	62	19	3

25106
 GENAISSANCE PHARMACEUTICALS
 5 SCIENCE PARK
 NEW HAVEN, CT 06511

CONFIRMATION NO. 3139

UPDATED FILING RECEIPT



0000000013836996

Date Mailed: 09/20/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Richard S. Judson, Guilford, CT;
 Andreas K. Windemuth, Woodbridge, CT;
 Chuanbo Xu, Madison, CT;

Power of Attorney: The patent practitioners associated with Customer Number 25106.

Domestic Priority data as claimed by applicant

This application is a 111(a) continuation of PCT/US00/17540, filed June 26, 2000, which
 claims priority to U.S. Provisional application 60/141,521 filed June 25, 1999

Foreign Applications

If Required, Foreign Filing License Granted: 06/03/2004

The number of your priority application, to be used for filing abroad under the Paris Convention is,
US10/019,243

Projected Publication Date: 12/30/2004

Non-Publication Request: No

Early Publication Request: No

RECEIVED

SEP 23 2004

Genaisance Pharmaceuticals
 Intellectual Property Dept.

Title

Methods for obtaining and using haplotype data

Preliminary Class

702

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.